Maxalt

Rizatriptan, the active ingredient in Maxalt, is a Triptan presented as a tablet for oral use. It provides rapid relief of migraine headache pain and associated symptoms such as nausea, photophobia, and phonophobia in adult patients.

GNH USA supplies Maxalt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU marketing‑authorization standards and is manufactured under GMP conditions. Our global distribution network ensures consistent quality and timely delivery to qualified healthcare providers.

Maxalt (rizatriptan) is indicated for the acute treatment of migraine, a neurovascular headache disorder.

Migraine without aura: reduces headache intensity and associated symptoms. Migraine with aura: alleviates headache after the aura phase. Acute migraine attacks: provides rapid relief of pain, nausea, photophobia and phonophobia.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient light‑headedness. - Fatigue: feeling unusually tired. - Dry mouth: reduced salivation. - Tingling or numbness: especially in the fingers or lips. - Chest discomfort: mild pressure or tightness.

Serious or Rare Side Effects: - Coronary vasospasm: chest pain due to reduced blood flow. - Serotonin syndrome: agitation, hyperthermia, rapid heart rate when combined with other serotonergic agents. - Severe allergic reaction: rash, swelling, difficulty breathing. - Hypertension: sudden increase in blood pressure. - Cardiac arrhythmia: irregular heart rhythms.

Before using Maxalt, consider the following safety measures. - Cardiovascular disease: avoid in patients with uncontrolled coronary artery disease. - History of stroke or transient ischemic attack: use with caution. - Concomitant serotonergic drugs: increased risk of serotonin syndrome. - Pregnancy: safety not established; discuss risks with a healthcare professional. - Pediatric use: not established for children. - Store at ambient temperature: keep below 25°C, protect from moisture and retain in the original packaging.

Rizatriptan may interact with other medicines; review the following categories.

Major Interactions (Avoid): - MAO inhibitors: risk of severe serotonin syndrome. - SSRIs, SNRIs, or other triptans: heightened serotonin toxicity. - Ergot alkaloids: additive vasoconstrictive effects.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may reduce the efficacy of rizatriptan. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase rizatriptan plasma levels. - CYP3A4 inducers (e.g., rifampin): decrease rizatriptan exposure.